Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 4Recurrence 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Carboplatin 346Cisplatin 240Paclitaxel 208Radiotherapy 207Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 147Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 102Etoposide 99Bevacizumab 96Specimen Handling 84Nivolumab 77Radiosurgery 74durvalumab 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 45Biopsy 43Radiation 42Irinotecan 42Topotecan 39Standard of Care 39Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Spermine Synthase × Thoracic × Clear all
NCT03075072 2024-10-23

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Dana-Farber Cancer Institute

Phase NA Active not recruiting
196 enrolled
BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡